A promising strategy in addressing obesity by targeting the amylin pathway involves utilizing dual amylin and calcitonin receptor agonists (DACRAs), that show superior metabolic effects compared to amylin analogues.212, 213. This evidence concerns the gene IAPP and obesity disorder.